Stocks / NASDAQ / Sophiris Bio, Inc.

Sophiris Bio, Inc.

Our Opinion

Sophiris Bio Inc is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in developing some of their medical products and treatments.

Supporting Evidence:

Report that specifies that the company conducts animal testing

“Preclinical data have also demonstrated PRX302 activity in treatment of prostate tumors using xenograft animal models.”

 

 

Company Description

Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. [Source: Reuters]

Company Website: http://www.sophirisbio.com/